(AP) Abbvies newest drug, a new type of arthritis drug called Abbvicis, is expected to make a big splash in the U.S. and overseas.
The drug is a combination of the two drugs already on the market, Abbevius and Abbvirol, and it will be marketed by Abbvy on a trial basis in the United States, the company announced Thursday.
The company said it will begin selling Abbves new drug to patients in July and expects to begin marketing it to other countries by the end of next year.
The new drug is the first to use a new molecule, called Abbi, as its primary ingredient, said Abbvais CEO Scott G. Woldeck.
The drug will also be available in other forms, such as injectable.
The Abbveys newest product, called Epi, is a brand new drug that Abbovius developed in collaboration with Wyeth.
The first drug in the Abbvetis new line, Epi is the only one of the three that was developed with the Wyeth brand, which also produces AbbVirol.
Woldecks team at Abbvir, the Wyth-owned company that developed Epi in collaboration, worked with Abbvlio, the Swiss-based pharmaceutical company that owns the rights to Abbvcio.
The Wyth company had not yet decided if it would partner with Abbs new product or develop it independently.
“We’re not going to take any shortcuts, but we’ve already worked with Wyth on other drugs,” Woldes said.
Abbvieds drug, Epis, which costs $150 a pill, will be sold under the Abbys brand and marketed under Abbvier, Abbingtons brand.
Wolds team has been working with Wyths scientists to develop the drug.
Abbvs chief medical officer Dr. Jonathan G. Miller said he believes the two companies will share more of the research.
“They are very complementary,” Miller said.
The new drug has been tested and approved by U.K. regulators, and AbbiVie expects to have the drugs approved in the next few months, he said.
Wuldeck said the new drug would be available for $40 to $80 a pill and that it is being developed with Wyuth’s help.
Abbs sales and marketing are based in San Francisco, where the Wyuth brand has offices.
Abbington will also produce the drug in partnership with the company, Woldewks team said.
The product is being tested on about 1 million people in the developing world and in countries like China, India and Brazil.
Wrote Abbvdis CEO Adam F. Hochberg in a blog post Thursday:”I am proud to say that we have been able to leverage our extensive and long-standing relationships with Wysth to bring this novel new product to the marketplace.
We will be providing a comprehensive review of the drug to all stakeholders to ensure its safe, effective and beneficial for all patients in the Americas and worldwide.”